Eurocor Tech - Life Sciences Technologies Interventional Cardiology Devices Endovascular Therapies

Dediacted to Your heart.
Life Sciences Technology.
Coronary stent technologies and special cardiovascular and endovascluar devices made in Europe for the world.


Date: 2016/07/13

The balloon is indicated for patients who undergo dialysis as they suffer from end stage renal failure. Stenosis and subsequent restenosis of the dialysis shunt graft is a common complication. The treatment of this stenosis is mandatory to protect AV fistulas and shunt grafts from early restenosis.
High pressure balloon is recommended for the treatment of AV fistulas, and shunt grafts as it reduces re-intervention and preserves future treatment options.

Bonn July 13, 2016 - Eurocor, an international specialist in medical DEB - technology, services and solutions, today announced that the FREEWAY™ – SHUNT BALLOON CATHETER (DEB) will be launched for arteriovenous (AV) access to help patients with end-stage renal disease.
FREEWAY™ – SHUNT DEB protects AV fistulas and shunt grafts from early restenosis and is a clinical proven therapeutical option for AV shunt patients. The feasibility study presented at LINC 2015, showed a low re-intervention rate of 11% at follow up.

More than 2.5 million end-stage renal disease patients worldwide are undergoing dialysis, a process of purifying the blood of a patient whose kidneys are not working normally. Dialysis achieves the extracorporeal removal of waste products such as creatinine, urea and free water from the blood when the kidneys are in a state of failure.

AV access sites are used to provide dialysis to patients. Due to repeated access restenosis and thickening of the vessel walls emerge. This can limit eventually shut down the dialysis access site. FREEWAY™ – SHUNT BALLOON CATHETER prevents restenosis, by opening the artery and distributing the anti-proliferative drug Paclitaxel to the vessel wall.

“We are happy and committed to present this option to Dialysis patients” says Mr. Lalit Mamtani, CEO Eurocor GmbH. “After basic research and the data derived from clinical studies the product efficacy is validated” said Dr. Rembert Pogge von Strandmann, Head of Eurocor Clinical Department.

Mr. Matthias Hautkappe, head of production at Eurocor, stated that the products are ready for shipment latest 31. July 2016.
Opto Circuits chairman Mr. Vinod Ramnani says “We are excited to launch this new generation shunt which will help extend the life of millions of patients around the world”.

Eurocor’s second-generation drug-eluting technology PTA balloon FREEWAY has been developed as an alternative to the limitations of existing therapeutic to PAD e.g. restenosis after POBA or stenting. The product provides good crossability, trackability and pushability and can be used where the use of other therapies is limited by the occurrence of high restenosis rates, anatomical challenges and stent fractures.
The coating makes the difference – FREEWAY uses a special homogenous coating
Eurocor’s DEB technology utilises a homogenous drug coating, which is released when the balloon is expanded. This inhibits the proliferation of smooth muscle cells, and may prevent restenosis by disturbing microtubule formation and thereby inhibiting cell division and migration. Paclitaxel is applied in a final concentration of 3 μg/mm² to the surface of the balloon.
FREEWAY™ features
• Clinically proven robust coating, with no drug loss on the way to target.
• Balloon lengths of 20 - 150 mm for Ø 2.0-8.0 mm with different shaft lengths
• Excellent catheter flexibility with tapered, hydrophilic shafts and low tip entry profiles




The Company:

Eurocor is a rapidly growing European Life Sciences Technology Corporation specializing in the research, development and manufacture of cardiovascular and endovascular products. Eurocor provides interventional physicians with innovative coronary stent technologies and special cardiovascular and endovascular devices, manufactured in Bonn. Products are indicated for minimally invasive cardiovascular and peripheral surgery and comply with biological and biomechanical principles to offer highly flexible, adaptable solutions. Extensive research and development, close clinician collaboration, outstanding quality standard philosophy and global scientific alliances lead to optimization of clinically effective technologies. Eurocor has designed an innovative method for balloon catheter drug delivery with high patient compliance. One heartbeat ahead® – with innovative products such as DIOR® and FREEWAY™.
Eurocor GmbH is a wholly owned subsidiary of Opto Eurocor Healthcare Limited and is part of the Opto Circuits Group.
For more information, please visit and